Evidation Health, which evaluates digital healthcare tools for outcomes comparison, will use $15 million in new funding to further automate portions of its clinical study process, recruit patients for studies faster and provide patients access to their health data during trials.

Formed by GE Ventures and Stanford Health Care, Evidation Health works with healthcare providers and payers, as well as pharmaceutical, biotechnology and digital healthcare companies, to evaluate digital healthcare tools—such as wearables and apps—through clinical trials and analysis. The company uses clinical trials to gather medical and behavioral data about the effectiveness of new digital healthcare applications and services for improving patient outcomes and lowering costs. The information gathered during the trial helps physicians, health systems and payers identify appropriate digital healthcare programs for use in patient care, the company says.

“We give patients the ability to provide their own health-related data to research through direct-to-patient trials aimed at improving health outcomes and reducing healthcare costs,” says Evidation Health CEO Dr. Deborah Kilpatrick. “Based on market benchmarking, we are enrolling patients into these population outcome studies 10 times faster than traditional clinical trials in a multi-center, clinical setting, but with population sizes that are often larger.”

Healthcare payers, pharma companies and healthcare systems hire Evidation Health to commission a trial to understand the effectiveness of their digital health program or conduct research to learn about the impact of patient behavior on outcomes and cost of care. Evidation declines to reveal how much it charges to conduct its research.

Evidation also partners with healthcare providers known for translational research, such as Brigham and Women’s Hospital and Ochsner Healthcare that can provide access to diverse patient populations across an array of therapeutic areas, demographics and locations for clinical studies.

The company’s Real Life Study Solution supports three kinds of studies. The first type is retrospective outcome studies that predict the potential impact of digital and traditional interventions on outcomes. The next is for  economic utility studies and economic impact analysis, which retrospectively and prospectively examines the economic impact of digital and traditional interventions across target populations, the company says. The third type of support is for prospective outcome studies that enroll target populations in structured protocols and registries to quantify the impact of digital and traditional interventions.

Evidation Health’s data gathering capability includes its behavior-to-outcomes analytics platform that quantifies the impact of patient behavior on health outcomes. The platform analyzes medical, contextual and behavioral data streams to quantify the value of digital health and traditional interventions.

For example, Evidation Health worked with a global pharmaceutical company using its behavior analysis platform to research 300,000 diabetes/dyslipidemia patients and segment that population into adherent behavior clusters. The platform collected longitudinal, real-life behavioral data and linked relevant behavioral activity such as diet and sleep patterns to medication adherence. The results provided insights into ways healthcare providers and pharma companies can promote better medication adherence to diabetics, the company says. Evidation Health didn’t name the drug manufacturer.